ReviewGerontology2022
Aging and Mesenchymal Stem Cells: Therapeutic Opportunities and Challenges in the Older Group.
Review in Gerontology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 44 citations in OpenAlex.
- Loss of EGFR activity in skeletal stem/progenitor cells is associated with impaired fracture healing in aged mice.Bioactive materials · 2027Article
- Maternal Endocrine and Vascular Perturbations Reprogram the Transcriptomic and Secretory Profile of Perinatal Stem Cells: A Comparative Study of Umbilical Cord-Derived Stem Cell UC-MSCs and Human Milk-Derived Stem Cell MM-MSCs.International journal of molecular sciences · 2026Article
- Angiogenic and Osteogenic Strategies for Skeletal Regeneration in Aging.Current osteoporosis reports · 2026Review
- Review
- Stem Cells in Aging and Anti-Aging.Stem cell reviews and reports · 2026Review
- Paracrine Induction of Cardiomyogenic Differentiation in Patient-Specific MSCs Using Conditioned Medium from iPSC-CMs.Biomedicines · 2026Article
- Mesenchymal stem/stromal cell-based therapies for autism spectrum disorder: emerging evidence and clinical prospects.Journal of translational medicine · 2026Review
- Bioreactors expansion of human mesenchymal stromal cell therapies: platforms, parameters, challenges and opportunities.Journal, genetic engineering & biotechnology · 2026Review
- Biologics for bone regeneration: advances in cell, protein, gene, and mRNA therapies.Bone research · 2026Review
- Senescence-Induced Lipidome Alterations in Mesenchymal Stromal Cells.Journal of proteome research · 2025Article
- Effect of Aging on the Morphofunctional Characteristics of Oral Cavity Mesenchymal Stromal Cells: A Scoping Review.Biomedicines · 2025Review
- Transcriptomic Analysis of the Effects of Hydroxysafflor Yellow A on hUC-MSC Senescence via the ECM-Receptor Interaction Pathway.International journal of molecular sciences · 2025Article
- Efficacy and safety of umbilical cord-derived mesenchymal stem cell-conditioned media for preventing and treating skin aging.World journal of stem cells · 2025Article
- Extracellular Vesicles of Adipose Multipotent Mesenchymal Stromal Cells Propagate Senescent Phenotype by Affecting PTEN Nuclear Import.International journal of molecular sciences · 2025Article
- Attenuation of primate aging via systemic infusion of senescence-resistant mesenchymal progenitor cells.Cell regeneration (London, England) · 2025Article
- Inhibition of GSK-3β Restores Differentiation Potential of Late-Passage Mesenchymal Stem Cells.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Mesenchymal Stem Cells Senescence: Mechanism and Rejuvenation Interventions.International journal of medical sciences · 2025Review
- Medical embryology and regenerative medicine: research and applications in clinical practice.Frontiers in cell and developmental biology · 2025Review
- Curcumin liposomes alleviate senescence of bone marrow mesenchymal stem cells by activating mitophagy.Scientific reports · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With aging, a portion of cells, including mesenchymal stem cells (MSCs), become senescent, and these senescent cells accumulate and promote various age-related diseases. Therefore, the older age group has become a major population for MSC therapy, which is aimed at improving tissue regeneration and function of the aged body. However, the application of MSC therapy is often unsatisfying in the aged group. One reasonable conjecture for this correlation is that aging microenvironment reduces the number and function of MSCs. Cellular senescence also plays an important role in MSC function impairment. Thus, it is necessary to explore the relationship between senescence and MSCs for improving the application of MSCs in the elderly. Here, we present the influence of aging on MSCs and the characteristics and functional changes of senescent MSCs. Furthermore, current therapeutic strategies for improving MSC therapy in the elderly group are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.